Today's Stocks Driving Success For The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 91 points (0.6%) at 15,561 as of Thursday, July 18, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,136 issues advancing vs. 784 declining with 110 unchanged.

The Drugs industry currently sits up 5.9% versus the S&P 500, which is up 0.5%. Top gainers within the industry include Herbalife ( HLF), up 5.0%, and Alexion Pharmaceuticals ( ALXN), up 1.6%. On the negative front, top decliners within the industry include Biogen Idec ( BIIB), down 0.9%, and Bristol-Myers Squibb Company ( BMY), down 0.5%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Sanofi ( SNY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Sanofi is up $0.64 (1.2%) to $52.84 on light volume. Thus far, 384,814 shares of Sanofi exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $52.23-$52.96 after having opened the day at $52.31 as compared to the previous trading day's close of $52.20.

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $139.2 billion and is part of the health care sector. Shares are up 10.2% year to date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Sanofi a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Sanofi Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Biotech Mailbag: Buy Dip in T2 Biosystems?

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids

Sanofi Has Good Potential Upside

European Pharma Companies Slip on MS Pricing Probe